Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 3/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 13/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 13/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4414014 | 0.87 | PRKDC (0.53) | PRKDCPIK3CDPIK3CBPIK3CAMTOR | |
| SCHEMBL4413883 | 0.87 | PRKDC (0.61) | PRKDCPIK3CDPIK3CBPIK3CAMTOR | |
| SCHEMBL4805433 | 0.86 | PRKDC (0.54) | PRKDCPIK3CDPIK3CBPIK3CAMTOR | |
| SCHEMBL4422989 | 0.82 | PIK3CB (0.58) | PRKDCPIK3CDPIK3CBPIK3CAMTOR | |
| SCHEMBL4413947 | 0.81 | PRKDC (0.55) | PRKDCPIK3CDPIK3CBPIK3CAMTOR | |
| SCHEMBL4417237 | 0.81 | PIK3CB (0.60) | PRKDCPIK3CDPIK3CBPIK3CAPIK3CG | |
| SCHEMBL13989472 | 0.80 | PIK3CB (0.56) | PRKDCPIK3CDPIK3CBPIK3CAMTOR | |
| SCHEMBL4415588 | 0.79 | PRKDC (0.58) | PRKDCPIK3CDPIK3CBPIK3CAMTOR | |
| SCHEMBL4551643 | 0.78 | PIK3CB (0.61) | PRKDCPIK3CDPIK3CBPIK3CAMTOR | |
| SCHEMBL4413873 | 0.75 | PRKDC (0.37) | PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572791-B2 | Therapeutic morpholino-substituted compounds | ASTRAZENECA AB (SE) | 2009-08-11 | — | — | US | disclosed |
| US-20080312233-A1 | Therapeutic Morpholino-Substituted Compounds | KINACIA PTY. LTD. (AU) | 2008-12-18 | — | — | US | disclosed |
| US-20080206312-A1 | Therapeutic Morpholino-Substituted Compounds | KINACIA PTY. LTD. (AU) | 2008-08-28 | — | — | US | disclosed |
| US-7405211-B2 | Using 2-morpholinyl-4H-pyrido(1,2-a)pyrimidin-4-one; enzyme inhibitors; antithrombotic agents ; restenosis; atherosclerosis; antihistamines; chronic obsessive pulminary disease; autoimmune diseases; anticancer agents; antiinflammatory agents | ASTRAZENECA AB (SE) | 2008-07-29 | — | — | US | disclosed |
| EP-1857443-A2 | Therapeutic morpholino-substituted compounds | AstraZeneca AB (SE) | 2007-11-21 | — | — | EP | disclosed |
| EP-1257537-B1 | THERAPEUTIC MORPHOLINO-SUBSTITUTED COMPOUNDS | ASTRAZENECA AB (SE) | 2007-05-30 | — | — | EP | disclosed |
| US-6977255-B2 | Therapeutic morpholino-substituted compounds | KINACIA PTY. LTD. (AU) | 2005-12-20 | — | — | US | disclosed |
| US-20050085471-A1 | Therapeutic morpholino-substituted compounds | KINACIA PTY LTD. | 2005-04-21 | — | — | US | disclosed |
| EP-1257537-A4 | THERAPEUTIC MORPHOLINO-SUBSTITUTED COMPOUNDS | KINACIA PTY LTD (AU) | 2003-04-23 | — | — | EP | disclosed |
| EP-1257537-A1 | THERAPEUTIC MORPHOLINO-SUBSTITUTED COMPOUNDS | Kinacia Pty Ltd (AU) | 2002-11-20 | — | — | EP | disclosed |
| WO-2001053266-A1 | THERAPEUTIC MORPHOLINO-SUBSTITUTED COMPOUNDS | KINACIA PTY LTD. (AU) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085471-A1 | Therapeutic morpholino-substituted compounds | PIK3CA, PTK2, PDPK1 | PRKDC 1024/4885PIK3CD 13/4885PIK3CB 14/4885 |
| US-20080206312-A1 | Therapeutic Morpholino-Substituted Compounds | PIK3CA, PTK2, PDPK1 | PRKDC 1026/4885PIK3CD 13/4885PIK3CB 14/4885 |
| US-20080312233-A1 | Therapeutic Morpholino-Substituted Compounds | PIK3CA, PTK2, PDPK1 | PRKDC 1026/4885PIK3CD 13/4885PIK3CB 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.